It's Time to Move Forward

LabCorp
800-444-9111
www.LabCorp.com

Quest Diagnostics
800-222-0446
www.QuestDiagnostics.com

CORE Diagnostics
2458 Embarcadero Way
Palo Alto, CA 94303
650-532-9500
info@corediagnostics.net
www.corediagnostics.net

Intelligene Diagnostics
10900 S. Clay Blair Blvd, Suite 1400
Olathe, KS 66061
913-258-2302
info@intelligenedx.com
www.intelligenedx.com

ARUP Laboratories
800-522-2787
www.ARUPLab.com/prosigna

University of Arizona Genetics Core – Clinical services division
1657 E Helen St
Tucson, AZ 85721
520-621-9791
uagcclinical.arl.arizona.edu

University of Kansas Medical Center
Clinical Molecular Oncology Laboratory
Andrew K Godwin PhD
3901 Rainbow Boulevard, Mail Stop 3040
Kansas City, KS 66160
USA
913-945-6391
cmol@kumc.edu
http://www.kumc.edu/school-of-medicine/pathology/clinical-molecular-oncology-laboratory.html

City of Hope Clinical Molecular Diagnostic Laboratory
1500 E. Duarte Rd
North West Building
Room 2236
Duarte, CA 91010
888-826-4362
mdl@coh.org

University of Alabama at Birmingham Comprehensive Cancer Center
www3.ccc.uab.edu

University of North Carolina Lineberger Comprehensive Cancer Center
www.unclineberger.org

University of Minnesota (Fairview Health Services)
2231 6th Street SE
Minneapolis, MN 55455
https://www.mhealth.org/

Moffitt Cancer Center
12902 USF Magnolia Drive
Tampa, FL 33612
https://moffitt.org/

Mayo Clinic Jacksonville
4500 San Pablo Road
Jacksonville, FL 32224
http://www.mayoclinic.org/patient-visitor-guide/florida

Baylor Scott & White Health
2401 S 31st
Temple, TX 7650
8254-724-2111
https://www.baylorscottandwhite.com/

Providence Health & Services, Oregon Regional Laboratories
4400 N. E. Halsey, Building #3
Portland, OR 97213
866-674-7990
prosigna@providence.org
http://oregon.providence.org/our-services/p/providence-laboratory-services/

Magee-Womens Hospital of UPMC
300 Halket St.
Pittsburgh, PA 15213
412-641-4651
dabbdj@mail.magee.edu

Geisinger Health System
100 North Academy Avenue
Danville, PA 17822
https://www.geisinger.org/en

Prosigna is helping oncologies around the world gain more information about their patients' risk of recurrence.

For additional assistance, contact info@prosigna.com

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.